Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Chim Lang, Dana Dawson, Michael Frenneaux (Lead / Corresponding author)

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

Original languageEnglish
Pages (from-to)693-698
Number of pages6
JournalFuture Cardiology
Volume10
Issue number6
DOIs
Publication statusPublished - 1 Nov 2014

Keywords

  • cardiac spectroscopy
  • diastole
  • ejection fraction
  • heart failure
  • perhexiline

Fingerprint Dive into the research topics of 'Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome'. Together they form a unique fingerprint.

  • Cite this

    Singh, S., Beadle, R., Cameron, D., Rudd, A., Bruce, M., Jagpal, B., Schwarz, K., Brindley, G., Mckiddie, F., Lang, C., Dawson, D., & Frenneaux, M. (2014). Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. Future Cardiology, 10(6), 693-698. https://doi.org/10.2217/fca.14.62